| Study Protocol Number | Study Title and Description |
|---|---|
| 26-0382 |
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR
To evaluate the efficacy of ALK-001 compared with placebo in slowing the progression of retinal atrophic lesion growth in participants with STGD |